🇺🇸 FDA
Patent

US 11547759

Bi-functional compounds and methods for targeted ubiquitination of androgen receptor

granted A61KA61K47/55A61P

Quick answer

US patent 11547759 (Bi-functional compounds and methods for targeted ubiquitination of androgen receptor) held by Montelino Therapeutics Inc. expires Mon Jan 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Montelino Therapeutics Inc.
Grant date
Tue Jan 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K47/55, A61P, A61P35/00